Skip to main content
Erschienen in: Inflammation 5/2021

26.05.2021 | Original Article

Downregulation of Cathepsin B Reduces Proliferation and Inflammatory Response and Facilitates Differentiation in Human HaCaT Keratinocytes, Ameliorating IL-17A and SAA-Induced Psoriasis-Like Lesion

verfasst von: Di Xu, Jie Wang

Erschienen in: Inflammation | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis is a common inflammatory dermatology disease. Strongly expressed serum amyloid A (SAA) promotes psoriasis exacerbation through inducing IL-17 secretion. What’s more, SAA can stimulate the release of cathepsin B. The current work was performed to demonstrate the specific effects of cathepsin B silencing on inflammatory response, proliferation, and differentiation of IL-17A and SAA-induced keratinocytes and to report the precise role of cathepsin B in psoriasis-like lesion. HaCaT keratinocytes received treatment with IL-17A (0, 10, 50, 100 ng/ml) or SAA (0, 1, 5, 10, 20 μg/ml) for 24 h to establish psoriasis-like keratinocytes model. HaCaT keratinocytes were transfected with small interfering RNA (siRNA)-cathepsin B for the functional experiments. Cathepsin B mRNA and protein levels were separately assessed by performing RT-qPCR and Western blot analysis. Then, CCK-8 for detection of cell proliferative capacity and Western blot assay for detection of Ki67 and PCNA expression were adopted to evaluate the influence of silenced cathepsin B on proliferation of IL-17A/SAA-induced HaCaT keratinocytes. Furthermore, IL-6, IL-1β, TNF-α, and p-NF-κB p65 were detected to assess the effects of cathepsin B knockdown on inflammatory response in IL-17A/SAA-induced HaCaT keratinocytes. In addition, assessment of KRT10, FLG, and LOR levels were applied to analyze the function of cathepsin B silencing on differentiation of IL-17A/SAA-induced HaCaT keratinocytes. Cathepsin B expression is distinctly elevated in IL-17A/SAA-induced HaCaT keratinocytes. IL-17A or SAA treatment enhanced proliferation, promoted the release of inflammatory factors, and arrested differentiation in HaCaT keratinocytes. Furthermore, downregulation of cathepsin B reduced proliferation, suppressed inflammatory response, and boosted differentiation in IL-17A/SAA-induced HaCaT keratinocytes. To sum up, cathepsin B silencing rescued excessive proliferation and inflammatory response and scarce differentiation in HaCaT keratinocytes induced by IL-17A and SAA. These findings prompted that cathepsin B might be a promising therapeutic target for psoriasis-like lesion, which helps to develop an anti-psoriatic agent.
Literatur
1.
Zurück zum Zitat Boehncke, W.H., and M.P. Schön. 2015. Psoriasis. Lancet 386: 983–994.CrossRef Boehncke, W.H., and M.P. Schön. 2015. Psoriasis. Lancet 386: 983–994.CrossRef
2.
Zurück zum Zitat Stein Gold, L., J.M. Jackson, M.L. Knuckles, and J.S. Weiss. 2016. Improvement in extensive moderate plaque psoriasis with a novel emollient spray formulation of betamethasone dipropionate 0.05. Journal of drugs in dermatology: JDD 15: 334–342.PubMed Stein Gold, L., J.M. Jackson, M.L. Knuckles, and J.S. Weiss. 2016. Improvement in extensive moderate plaque psoriasis with a novel emollient spray formulation of betamethasone dipropionate 0.05. Journal of drugs in dermatology: JDD 15: 334–342.PubMed
3.
Zurück zum Zitat Arbiser, J.L., and J. Elsey. 2018. Targeting the plasticity of psoriasis. The Journal of Investigative Dermatology 138: 734–736.CrossRef Arbiser, J.L., and J. Elsey. 2018. Targeting the plasticity of psoriasis. The Journal of Investigative Dermatology 138: 734–736.CrossRef
4.
Zurück zum Zitat Yang, L., W. Guo, S. Zhang, and G. Wang. 2018. Ubiquitination-proteasome system: a new player in the pathogenesis of psoriasis and clinical implications. Journal of Dermatological Science 89: 219–225.CrossRef Yang, L., W. Guo, S. Zhang, and G. Wang. 2018. Ubiquitination-proteasome system: a new player in the pathogenesis of psoriasis and clinical implications. Journal of Dermatological Science 89: 219–225.CrossRef
5.
Zurück zum Zitat Li, H.J., N.L. Wu, C.M. Pu, C.Y. Hsiao, D.C. Chang, and C.F. Hung. 2020. Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides. Scientific Reports 10: 2932.CrossRef Li, H.J., N.L. Wu, C.M. Pu, C.Y. Hsiao, D.C. Chang, and C.F. Hung. 2020. Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides. Scientific Reports 10: 2932.CrossRef
6.
Zurück zum Zitat Liu, M., G. Zhang, S. Naqvi, F. Zhang, T. Kang, Q. Duan, Z. Wang, S. Xiao, and Y. Zheng. 2020. Cytotoxicity of Saikosaponin A targets HEKa cell through apoptosis induction by ROS accumulation and inflammation suppression via NF-κB pathway. International Immunopharmacology 86: 106751.CrossRef Liu, M., G. Zhang, S. Naqvi, F. Zhang, T. Kang, Q. Duan, Z. Wang, S. Xiao, and Y. Zheng. 2020. Cytotoxicity of Saikosaponin A targets HEKa cell through apoptosis induction by ROS accumulation and inflammation suppression via NF-κB pathway. International Immunopharmacology 86: 106751.CrossRef
7.
Zurück zum Zitat Ma, J., S. Feng, D. Ai, Y. Liu, and X. Yang. 2019. D-pinitol ameliorates imiquimod-induced psoriasislike skin inflammation in a mouse model via the NF-κB pathway. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer 38: 285–295.CrossRef Ma, J., S. Feng, D. Ai, Y. Liu, and X. Yang. 2019. D-pinitol ameliorates imiquimod-induced psoriasislike skin inflammation in a mouse model via the NF-κB pathway. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer 38: 285–295.CrossRef
8.
Zurück zum Zitat Zhou, W., M. Hu, X. Zang, Q. Liu, J. Du, J. Hu, L. Zhang, Z. Du, and Z. Xiang. 2020. Luteolin attenuates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 131: 110696.CrossRef Zhou, W., M. Hu, X. Zang, Q. Liu, J. Du, J. Hu, L. Zhang, Z. Du, and Z. Xiang. 2020. Luteolin attenuates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 131: 110696.CrossRef
9.
Zurück zum Zitat Gursky, O. 2020. Structural basis for vital function and malfunction of serum amyloid A: an acute-phase protein that wears hydrophobicity on its sleeve. Current Atherosclerosis Reports 22: 69.CrossRef Gursky, O. 2020. Structural basis for vital function and malfunction of serum amyloid A: an acute-phase protein that wears hydrophobicity on its sleeve. Current Atherosclerosis Reports 22: 69.CrossRef
10.
Zurück zum Zitat Morizane, S., K. Mizuno, T. Takiguchi, S. Sugimoto, and K. Iwatsuki. 2017. The involvement of serum amyloid A in psoriatic inflammation. The Journal of Investigative Dermatology 137: 757–760.CrossRef Morizane, S., K. Mizuno, T. Takiguchi, S. Sugimoto, and K. Iwatsuki. 2017. The involvement of serum amyloid A in psoriatic inflammation. The Journal of Investigative Dermatology 137: 757–760.CrossRef
11.
Zurück zum Zitat Choi, M., M.O. Kim, J. Lee, J. Jeong, Y. Sung, S. Park, W. Kwon, S. Jang, S.J. Park, H.S. Kim, W.Y. Jang, S.H. Kim, S. Lee, S.K. Choi, and Z.Y. Ryoo. 2019. Hepatic serum amyloid A1 upregulates interleukin-17 (IL-17) in γδ T cells through Toll-like receptor 2 and is associated with psoriatic symptoms in transgenic mice. Scandinavian Journal of Immunology 89: e12764.CrossRef Choi, M., M.O. Kim, J. Lee, J. Jeong, Y. Sung, S. Park, W. Kwon, S. Jang, S.J. Park, H.S. Kim, W.Y. Jang, S.H. Kim, S. Lee, S.K. Choi, and Z.Y. Ryoo. 2019. Hepatic serum amyloid A1 upregulates interleukin-17 (IL-17) in γδ T cells through Toll-like receptor 2 and is associated with psoriatic symptoms in transgenic mice. Scandinavian Journal of Immunology 89: e12764.CrossRef
12.
Zurück zum Zitat Yu, N., S. Zhang, J. Lu, Y. Li, X. Yi, L. Tang, L. Su, and Y. Ding. 2017. Serum amyloid A, an acute phase protein, stimulates proliferative and proinflammatory responses of keratinocytes. Cell Proliferation 50: e12320.CrossRef Yu, N., S. Zhang, J. Lu, Y. Li, X. Yi, L. Tang, L. Su, and Y. Ding. 2017. Serum amyloid A, an acute phase protein, stimulates proliferative and proinflammatory responses of keratinocytes. Cell Proliferation 50: e12320.CrossRef
13.
Zurück zum Zitat Fujita, Y., N. Matsuoka, J. Temmoku, M.Y. Furuya, T. Asano, S. Sato, H. Kobayashi, H. Watanabe, E. Suzuki, T. Urano, H. Kozuru, H. Yatsuhashi, T. Koga, A. Kawakami, and K. Migita. 2019. Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils. Arthritis Research & Therapy 21: 250.CrossRef Fujita, Y., N. Matsuoka, J. Temmoku, M.Y. Furuya, T. Asano, S. Sato, H. Kobayashi, H. Watanabe, E. Suzuki, T. Urano, H. Kozuru, H. Yatsuhashi, T. Koga, A. Kawakami, and K. Migita. 2019. Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils. Arthritis Research & Therapy 21: 250.CrossRef
14.
Zurück zum Zitat Hirai, T., T. Kanda, K. Sato, M. Takaishi, K. Nakajima, M. Yamamoto, R. Kamijima, J. Digiovanni, and S. Sano. 2013. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation. The Journal of immunology: official journal of the American Association of Immunologists 190: 4805–4811.CrossRef Hirai, T., T. Kanda, K. Sato, M. Takaishi, K. Nakajima, M. Yamamoto, R. Kamijima, J. Digiovanni, and S. Sano. 2013. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation. The Journal of immunology: official journal of the American Association of Immunologists 190: 4805–4811.CrossRef
15.
Zurück zum Zitat Guo, J., J. Tu, Y. Hu, G. Song, and Z. Yin. 2019. Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis. Drug Design, Development and Therapy 13: 581–588.CrossRef Guo, J., J. Tu, Y. Hu, G. Song, and Z. Yin. 2019. Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis. Drug Design, Development and Therapy 13: 581–588.CrossRef
16.
Zurück zum Zitat Schwenck, J., A. Maurer, B. Fehrenbacher, R. Mehling, P. Knopf, N. Mucha, D. Haupt, K. Fuchs, C.M. Griessinger, D. Bukala, J. Holstein, M. Schaller, I.G. Menendez, K. Ghoreschi, L. Quintanilla-Martinez, M. Gütschow, S. Laufer, T. Reinheckel, M. Röcken, H. Kalbacher, B.J. Pichler, and M. Kneilling. 2019. Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions. Theranostics 9: 3903–3917.CrossRef Schwenck, J., A. Maurer, B. Fehrenbacher, R. Mehling, P. Knopf, N. Mucha, D. Haupt, K. Fuchs, C.M. Griessinger, D. Bukala, J. Holstein, M. Schaller, I.G. Menendez, K. Ghoreschi, L. Quintanilla-Martinez, M. Gütschow, S. Laufer, T. Reinheckel, M. Röcken, H. Kalbacher, B.J. Pichler, and M. Kneilling. 2019. Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions. Theranostics 9: 3903–3917.CrossRef
17.
Zurück zum Zitat Liu, C., Z. Cai, T. Hu, Q. Yao, and L. Zhang. 2020. Cathepsin B aggravated doxorubicin-induced myocardial injury via NF-κB signalling. Molecular Medicine Reports 22: 4848–4856.CrossRef Liu, C., Z. Cai, T. Hu, Q. Yao, and L. Zhang. 2020. Cathepsin B aggravated doxorubicin-induced myocardial injury via NF-κB signalling. Molecular Medicine Reports 22: 4848–4856.CrossRef
18.
Zurück zum Zitat Savage, C.D., G. Lopez-Castejon, A. Denes, and D. Brough. 2012. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Frontiers in Immunology 3: 288.CrossRef Savage, C.D., G. Lopez-Castejon, A. Denes, and D. Brough. 2012. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Frontiers in Immunology 3: 288.CrossRef
19.
Zurück zum Zitat Yu, J., H. Zhu, S. Taheri, W. Mondy, L. Bonilha, G.S. Magwood, D. Lackland, R.J. Adams, and M.S. Kindy. 2019. Serum amyloid A-mediated inflammasome activation of microglial cells in cerebral ischemia. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 39: 9465–9476.CrossRef Yu, J., H. Zhu, S. Taheri, W. Mondy, L. Bonilha, G.S. Magwood, D. Lackland, R.J. Adams, and M.S. Kindy. 2019. Serum amyloid A-mediated inflammasome activation of microglial cells in cerebral ischemia. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 39: 9465–9476.CrossRef
20.
Zurück zum Zitat Ma, W.Y., K. Jia, and Y. Zhang. 2016. IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα. Experimental and Therapeutic Medicine 11: 631–636.CrossRef Ma, W.Y., K. Jia, and Y. Zhang. 2016. IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα. Experimental and Therapeutic Medicine 11: 631–636.CrossRef
21.
Zurück zum Zitat Vallejo, A., B. Chami, J.M. Dennis, M. Simone, G. Ahmad, A.I. Abdo, A. Sharma, W.A. Shihata, N. Martin, J. Chin-Dusting, J.B. de Haan, and P.K. Witting. 2018. NFκB inhibition mitigates serum amyloid A-induced pro-atherogenic responses in endothelial cells and leukocyte adhesion and adverse changes to endothelium function in isolated aorta. International Journal of Molecular Sciences 20: 105.CrossRef Vallejo, A., B. Chami, J.M. Dennis, M. Simone, G. Ahmad, A.I. Abdo, A. Sharma, W.A. Shihata, N. Martin, J. Chin-Dusting, J.B. de Haan, and P.K. Witting. 2018. NFκB inhibition mitigates serum amyloid A-induced pro-atherogenic responses in endothelial cells and leukocyte adhesion and adverse changes to endothelium function in isolated aorta. International Journal of Molecular Sciences 20: 105.CrossRef
22.
Zurück zum Zitat Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods: a companion to Methods in enzymology 25: 402–408.CrossRef Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods: a companion to Methods in enzymology 25: 402–408.CrossRef
23.
Zurück zum Zitat Sakkas, L.I., and D.P. Bogdanos. 2017. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmunity Reviews 16: 10–15.CrossRef Sakkas, L.I., and D.P. Bogdanos. 2017. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmunity Reviews 16: 10–15.CrossRef
24.
Zurück zum Zitat Zhuang, L., W. Ma, J. Yan, and H. Zhong. 2020. Evaluation of the effects of IL-22 on the proliferation and differentiation of keratinocytes in vitro. Molecular Medicine Reports 22: 2715–2722.PubMedPubMedCentral Zhuang, L., W. Ma, J. Yan, and H. Zhong. 2020. Evaluation of the effects of IL-22 on the proliferation and differentiation of keratinocytes in vitro. Molecular Medicine Reports 22: 2715–2722.PubMedPubMedCentral
25.
Zurück zum Zitat Abe, S., M. Ueno, M. Nishitani, T. Akamatsu, T. Sato, M. Shimoda, H. Kanaoka, Y. Nii, H. Yamasaki, and K. Yuasa. 2020. Citrus sudachi peel extract suppresses cell proliferation and promotes the differentiation of keratinocytes through inhibition of the EGFR-ERK signaling pathway. Biomolecules 10. Abe, S., M. Ueno, M. Nishitani, T. Akamatsu, T. Sato, M. Shimoda, H. Kanaoka, Y. Nii, H. Yamasaki, and K. Yuasa. 2020. Citrus sudachi peel extract suppresses cell proliferation and promotes the differentiation of keratinocytes through inhibition of the EGFR-ERK signaling pathway. Biomolecules 10.
26.
Zurück zum Zitat Sun, C., and J. Xia. 2020. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Medica 111: 254–265.PubMed Sun, C., and J. Xia. 2020. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Medica 111: 254–265.PubMed
27.
Zurück zum Zitat Zhang, J., J. Zhang, Q. Lin, L. Chen, and Y. Song. 2021. IL-17 promotes proliferation, inflammation and inhibits apoptosis of HaCaT cells via interacting with the TRAF3 interacting protein 2. Experimental and Therapeutic Medicine 21: 49.CrossRef Zhang, J., J. Zhang, Q. Lin, L. Chen, and Y. Song. 2021. IL-17 promotes proliferation, inflammation and inhibits apoptosis of HaCaT cells via interacting with the TRAF3 interacting protein 2. Experimental and Therapeutic Medicine 21: 49.CrossRef
28.
Zurück zum Zitat Chorachoo, J., S. Lambert, T. Furnholm, L. Roberts, L. Reingold, S. Auepemkiate, S.P. Voravuthikunchai, and A. Johnston. 2018. The small molecule rhodomyrtone suppresses TNF-α and IL-17A-induced keratinocyte inflammatory responses: a potential new therapeutic for psoriasis. PLoS One 13: e0205340.CrossRef Chorachoo, J., S. Lambert, T. Furnholm, L. Roberts, L. Reingold, S. Auepemkiate, S.P. Voravuthikunchai, and A. Johnston. 2018. The small molecule rhodomyrtone suppresses TNF-α and IL-17A-induced keratinocyte inflammatory responses: a potential new therapeutic for psoriasis. PLoS One 13: e0205340.CrossRef
29.
Zurück zum Zitat Yu, N., S. Liu, X. Yi, S. Zhang, and Y. Ding. 2015. Serum amyloid A induces interleukin-1β secretion from keratinocytes via the NACHT, LRR and PYD domains-containing protein 3 inflammasome. Clinical and Experimental Immunology 179: 344–353.CrossRef Yu, N., S. Liu, X. Yi, S. Zhang, and Y. Ding. 2015. Serum amyloid A induces interleukin-1β secretion from keratinocytes via the NACHT, LRR and PYD domains-containing protein 3 inflammasome. Clinical and Experimental Immunology 179: 344–353.CrossRef
30.
Zurück zum Zitat Couderc, E., F. Morel, P. Levillain, A. Buffière-Morgado, M. Camus, C. Paquier, C. Bodet, J.F. Jégou, M. Pohin, L. Favot, M. Garcia, V. Huguier, J. Mcheik, C. Lacombe, H. Yssel, G. Guillet, F.X. Bernard, and J.C. Lecron. 2017. Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis. PLoS One 12: e0181486.CrossRef Couderc, E., F. Morel, P. Levillain, A. Buffière-Morgado, M. Camus, C. Paquier, C. Bodet, J.F. Jégou, M. Pohin, L. Favot, M. Garcia, V. Huguier, J. Mcheik, C. Lacombe, H. Yssel, G. Guillet, F.X. Bernard, and J.C. Lecron. 2017. Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis. PLoS One 12: e0181486.CrossRef
Metadaten
Titel
Downregulation of Cathepsin B Reduces Proliferation and Inflammatory Response and Facilitates Differentiation in Human HaCaT Keratinocytes, Ameliorating IL-17A and SAA-Induced Psoriasis-Like Lesion
verfasst von
Di Xu
Jie Wang
Publikationsdatum
26.05.2021
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 5/2021
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-021-01477-0

Weitere Artikel der Ausgabe 5/2021

Inflammation 5/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.